Cognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: study protocol for a randomized controlled trial
dc.contributor.author | González Ortega, Itxaso | |
dc.contributor.author | Echeburúa Odriozola, Enrique | |
dc.contributor.author | García-Alocén, Adriana | |
dc.contributor.author | Vega, Patricia | |
dc.contributor.author | González Pinto Arrillaga, Ana María | |
dc.date.accessioned | 2019-04-10T10:40:34Z | |
dc.date.available | 2019-04-10T10:40:34Z | |
dc.date.issued | 2016-07-29 | |
dc.identifier.citation | Trials 17 : (2016) // Article ID 372 | es_ES |
dc.identifier.issn | 1745-6215 | |
dc.identifier.uri | http://hdl.handle.net/10810/32407 | |
dc.description.abstract | Background: The high rate of cannabis use among patients with first-episode psychosis (FEP), as well as the associated negative impact on illness course and treatment outcomes, underlines the need for effective interventions in these populations. However, to date, there have been few clinical treatment trials (of pharmacological or psychological interventions) that have specifically focused on addressing comorbid cannabis use among these patients. The aim of this paper is to describe the design of a study protocol for a randomized controlled trial in which the objective is to assess the efficacy of a specific cognitive behavioral therapy program for cannabis cessation in patients with FEP compared to standard treatment (psychoeducation). Methods/design: This is a single-blind randomized study with 1 year of follow-up. Patients are to be randomly assigned to one of two treatments: (1) specific cognitive behavioral therapy for cannabis cessation composed of 1-hour sessions once a week for 16 weeks, in addition to pharmacological treatment scheduled by the psychiatrist, or (2) a control group (psychoeducation + pharmacological treatment) following the same format as the experimental group. Participants in both groups will be evaluated at baseline (pre-treatment), at 16 weeks (post-treatment), and at 3 and 6 months and 1 year of follow-up. The primary outcome will be that patients in the experimental group will have greater cannabis cessation than patients in the control group at post-treatment. The secondary outcome will be that the experimental group will have better clinical and functional outcomes than the control group. Discussion: This study provides the description of a clinical trial design based on specific cognitive behavioral therapy for cannabis cessation in FEP patients, aiming to improve clinical and functional outcome, as well as tackling the addictive disorder. | es_ES |
dc.description.sponsorship | This study is funded by the Spanish Ministry of Economy and Competitiveness, through the Carlos III Health Institute (ISCIII), and the European Regional Development Fund (ERDF) (PI13/02252). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Biomed Central | es_ES |
dc.relation | info:eu-repo/grantAgreement/MINECO/PI13/02252 | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | cannabis | es_ES |
dc.subject | first-episode psychosis | es_ES |
dc.subject | psychological treatment | es_ES |
dc.subject | age-of-onset | es_ES |
dc.subject | 1st episode psychosis | es_ES |
dc.subject | clinical high-risk | es_ES |
dc.subject | medication adherence | es_ES |
dc.subject | predictive-validity | es_ES |
dc.subject | anandamide levels | es_ES |
dc.subject | use disorders | es_ES |
dc.subject | substance use | es_ES |
dc.subject | young-people | es_ES |
dc.subject | schizophrenia | es_ES |
dc.title | Cognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: study protocol for a randomized controlled trial | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-016-1507-x | es_ES |
dc.identifier.doi | 10.1186/s13063-016-1507-x | |
dc.departamentoes | Neurociencias | es_ES |
dc.departamentoes | Personalidad, evaluación y tratamiento psicológico | es_ES |
dc.departamentoeu | Neurozientziak | es_ES |
dc.departamentoeu | Nortasuna, balioespena eta psikologia tratamendua | es_ES |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.